DuChemBIO Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Operating Revenue	35,656	35,601	34,695
Other Revenue	-	-	-0
Revenue	35,656	35,601	34,695
Revenue Growth (YoY)	-	2.61%	-
Cost of Revenue	23,393	23,367	22,898
Gross Profit	12,263	12,234	11,797
Selling, General & Admin	5,754	5,548	5,087
Research & Development	-	-	205.31
Operating Expenses	7,308	7,158	6,541
Operating Income	4,955	5,076	5,256
Interest Expense	-1,009	-1,091	-1,364
Interest & Investment Income	114.79	89.64	90.89
Earnings From Equity Investments	755.64	1,106	-69.64
Currency Exchange Gain (Loss)	-24.93	-34.84	-7.99
Other Non Operating Income (Expenses)	20.93	30.23	68.38
EBT Excluding Unusual Items	4,812	5,177	3,974
Gain (Loss) on Sale of Investments	387.82	387.82	92.13
Gain (Loss) on Sale of Assets	-0.18	-0.18	16.28
Asset Writedown	-	-	-30.7
Pretax Income	5,199	5,564	4,052
Income Tax Expense	-2,410	-2,429	51.23
Net Income	7,609	7,994	4,001
Net Income to Common	7,609	7,994	4,001
Net Income Growth	-	99.82%	-
Shares Outstanding (Basic)	27	27	27
Shares Outstanding (Diluted)	27	27	27
Shares Change (YoY)	-	0.43%	-
EPS (Basic)	279.09	297.54	149.54
EPS (Diluted)	279.09	297.54	149.54
EPS Growth	-	98.97%	-
Free Cash Flow	5,174	5,440	7,293
Free Cash Flow Per Share	189.76	202.48	272.63
Gross Margin	34.39%	34.36%	34.00%
Operating Margin	13.90%	14.26%	15.15%
Profit Margin	21.34%	22.45%	11.53%
Free Cash Flow Margin	14.51%	15.28%	21.02%
EBITDA	10,565	10,641	11,016
EBITDA Margin	29.63%	29.89%	31.75%
D&A For EBITDA	5,610	5,565	5,760
EBIT	4,955	5,076	5,256
EBIT Margin	13.90%	14.26%	15.15%
Effective Tax Rate	-	-	1.26%
Advertising Expenses	-	76.18	62.35

Source: S&P Global Market Intelligence. Standard template. Financial Sources.